account_id none on file
legal_name Cero Therapeutics Holdings, Inc.
ticker CERO
cik 1870404
domain cero.bio
linkedin_company_url https://www.linkedin.com/company/cero-therapeutics
entry_point_account_id none on file
name CERo Therapeutics Holdings Inc.
exchange OTC
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 12 executives 1 family 0
why_nownone on file
callsnone on file
filings
its general and administrative expenses will increase in the future as the Company increases headcount and contracted services for operational
filing / Aug 14, 2026 / receipt
its R&D expenses may increase in the future if the Company increases headcount, compensation expense, and contracted services for
filing / Aug 14, 2026 / receipt
December 31, 2025, the Company holds a five-year lease for laboratory and office space expiring in September 2026. The lease has escalating
filing / Aug 14, 2026 / receipt
its general and administrative expenses will increase in the future as the Company increases headcount and contracted services for operational
filing / Aug 14, 2026 / receipt
its R&D expenses may increase in the future if the Company increases headcount, compensation expense, and contracted services for
filing / Aug 14, 2026 / receipt
December 31, 2025, the Company holds a five-year lease for laboratory and office space expiring in September 2026. The lease has escalating
filing / Aug 14, 2026 / receipt
Company anticipates that its general and administrative expenses will increase in the future as the Company increases headcount and contracted
filing / May 15, 2026 / receipt
Company anticipates that its R&D expenses will significantly increase in the future as the Company increases headcount, compensation
filing / May 15, 2026 / receipt
of March 31, 2026 and December 31, 2025, the Company holds a five-year lease for laboratory and office space expiring in September 2026.
filing / May 15, 2026 / receipt
Company anticipates that its general and administrative expenses will increase in the future as the Company increases headcount and contracted
filing / May 15, 2026 / receipt
Company anticipates that its R&D expenses will significantly increase in the future as the Company increases headcount, compensation
filing / May 15, 2026 / receipt
of March 31, 2026 and December 31, 2025, the Company holds a five-year lease for laboratory and office space expiring in September 2026.
filing / May 15, 2026 / receipt
executives
| Chris Ehrlich | Interim Chief Executive Officer | - | receipt |
familynone on file
upcomingnone on file
changes
| 2024-12-06 | Interim Chief Executive Officer, appointed | sec_8k |
| 2024-10-02 | Chief Financial Officer, departed | sec_8k |
mcp_package_hint
slug cero-therapeutics-holdings-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$